- Price
- $4.27
- Day
- +3.64%
- Mkt Cap
- $255.69M
- 52W Range
- $2.20 – $5.42
- Volume
- 151.1K
- Beta
- 0.48
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO
Affinity Asset Advisors LLC lessened its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 402,550 shares of the company's stock after selling 170,254 shares during the quarter. Affinity Asset Advisors
Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for medical devices, relying on Medtronic and Terumo for commercialization. Medtronic and Terumo have invested a combined $146 million, with OBIO's $220 million valuation reflecting a modest premium to strategic funding and with significant potential upside as catalysts approach.